Skip to main content
×
Blacklisted Listed News Logo
Menu - Navigation
Menu - Navigation

Cited Sources

2nd Smartest Guy in the World
2nd Amendment Shirts
10th Amendment Center
Aaron Mate
Activist Post
AIER
Aletho News
Ammo.com
AmmoLand
Alliance for Natural Health, The
Alt-Market
American Free Press
Antiwar
Armstrong Economics
Art of Liberty
AUTOMATIC EARTH, The
Ben Bartee
Benny Wills
Big League Politics
Black Vault, The
BOMBTHROWER
Brandon Turbeville
Breaking Defense
Breitbart
Brownstone Institute
Burning Platform, The
Business Insider
Business Week
Caitlin Johnstone
Campus Reform
CAPITALIST EXPLOITS
Charles Hugh Smith
Children's Health Defense
CHRISTOPHE BARRAUD
Chris Wick
CIAgate
Citizen Free Press
Citizens for Legit Gov.
CNN Money
Collective Evolution
Common Dreams
Conscious Resistance Network
Corbett Report
Counter Signal, The
Cryptogon
Cryptome
Daily Bell, The
Daily Reckoning, The
Daily Veracity
DANERIC'S ELLIOTT WAVES
Dark Journalist
David Haggith
Defense Industry Daily
Defense Link
Defense One
Dennis Broe
DOLLAR COLLAPSE
DR. HOUSING BUBBLE
Dr. Robert Malone
Drs. Wolfson
Drudge Report
Economic Collapse, The
ECONOMIC POPULIST, The
Electronic Frontier Foundation
Ellen Brown
Emerald Robinson
Expose, The
F. William Engdahl
FAIR
Farm Wars
Faux Capitalist
FINANCIAL REVOLUTIONIST
Forbes
Foreign Policy Journal
FOREXLIVE
Foundation For Economic Freedom
Free Thought Project, The
From Behind Enemy Lines
From The Trenches
FUNDIST
Future of Freedom Foundation
Futurism
GAINS PAINS & CAPITAL
GEFIRA
Geopolitical Monitor
Glenn Greenwald
Global Research
Global Security
GM RESEARCH
GOLD CORE
Grayzone, The
Great Game India
Guadalajara Geopolitics
Helen Caldicott
Homeland Sec. Newswire
Human Events
I bank Coin
IEEE
IMPLODE-EXPLODE
Information Clearing House
Information Liberation
Infowars
Insider Paper
Intel News
Intercept, The
Jane's
Jay's Analysis
Jeff Rense
John Adams
John Pilger
John W. Whitehead
Jonathan Cook
Jon Rappoport
Jordan Schachtel
Just The News
Kevin Barret
Kitco
Last American Vagabond, The
Lew Rockwell
Le·gal In·sur·rec·tion
Libertarian Institute, The
Libertas Bella
LIBERTY BLITZKRIEG
LIBERTY Forcast
Liberty Unyielding
Market Oracle
Market Watch
Maryanne Demasi
Matt Taibbi
Medical Express
Media Monarchy
Mercola
Michael Snyder
Michael Tracey
Middle East Monitor
Mike "Mish" Shedlock
Military Info Tech
Mind Unleashed, The
Mint Press
MISES INSTITUTE
Mises Wire
MISH TALK
Money News
Moon of Alabama
Motherboard
My Budget 360
Naked Capitalism
Natural News
New American, The
New Eastern Outlook
News Deck
New World Next Week
Nicholas Creed
OF TWO MINDS
Off-Guardian
Oil Price
OPEN THE BOOKS
Organic Prepper, The
PANDEMIC: WAR ROOM
PETER SCHIFF
Phantom Report
Pierre Kory
Political Vigilante
Public Intelligence
Rair
Reclaim The Net
Revolver
Richard Dolan
Right Turn News
Rokfin
RTT News
Rutherford Institute
SAFEHAVEN
SAKER, The
Shadow Stats
SGT Report
Shadowproof
Slay News
Slog, The
SLOPE OF HOPE
Solari
South Front
Sovereign Man
Spacewar
spiked
SPOTGAMMA
Steve Kirsch
Steve Quayle
Strange Sounds
Strike The Root
Summit News
Survival Podcast, The
Tech Dirt
Technocracy News
Techno Fog
Terry Wahls, M.D.
TF METALS REPORT
THEMIS TRADING
Tom Renz
True Activist
unlimited hangout
UNREDACTED
Unreported Truths
Unz Review, The
VALUE WALK
Vigilant Citizen
Voltaire
Waking Times
Wall Street Journal
Wallstreet on Parade
Wayne Madsen
What Really Happened
Whitney Webb
winter oak
Wolf Street
Zero Hedge

Magic mushroom treatment on par with pharma drugs for combating depression, study finds

Published: April 15, 2021 | Print Friendly and PDF
  Gab
Share

Source: RT

In a small phase two trial, Imperial College researchers have found that psilocybin, the active ingredient of magic mushrooms, is at least as effective as pharmaceutical medication at treating depression.

In their admittedly small scale study, some 59 volunteers with depression were split into two groups.

One group was given a daily dosage of the widely used antidepressant escitalopram (AKA Lexapro, Cipralex, and others). They were also administered very weak doses of psilocybin twice, three weeks apart, over the course of the study.

The second group received much stronger doses of psilocybin, with a placebo instead of antidepressant medication.

After six weeks, the self-reported results from the patients suggested the psilocybin was just as effective as the pharmaceutical, and in many cases showed a slightly bigger – but ultimately statistically insignificant – improvement in symptoms.

The research team, led by Imperial College London neuroscientist Robin Carhart‑Harris, also highlighted the limited timeframe of the study as playing an important factor in the results, and suggested that a longer study might yield different results, possibly favouring pharmaceutical intervention.

The scientists were also quick to highlight the importance of guided psychotherapy to manage any hallucinatory experiences among the trial volunteers, lest members of the public attempt to self-medicate.

“We strongly believe that the … psychotherapy component is as important as the drug action,” Carhart-Harris said.

“With a psychedelic it is more about a release of thought and feeling that, when guided with psychotherapy, produces positive outcomes.”

Some five patients taking the SSRI stopped or reduced their doses due to negative effects, but none in the psilocybin group did. Furthermore, volunteers with a family history of psychosis were excluded from the trial, which may have tipped the results positively in favour of the psychedelic intervention.

Previous research has found that psilocybin treatment had fewer side effects and had an almost immediate impact compared with common antidepressant medication, such as selective serotonin reuptake inhibitors (SSRIs).

SSRIs are often perceived to blunt emotional response, whereas the psilocybin had the opposite effect, according to fMRI scans which showed an apparent increase in emotional connections within the patients’ brains.

There are often a slew of side effects associated with SSRIs, ranging from lethargy and mood swings to so-called ‘brain zaps’, or the sensation of electrical shocks in the brain associated with the use (or discontinuation) of the medication.

SSRIs also typically have a lead time of up to six weeks to reach full effect, while ongoing side effects which can persist beyond this initial phase include insomnia, weight gain, and persistent fatigue, among others.

Further, the efficacy of such antidepressants can wane for some patients over time, so breakthroughs in the field of psychedelic treatments may provide huge relief for patients with adverse reactions to the more common interventions – though it is still too early to make any sweeping assertions about psilocybin treatments among the wider populace.

Still, with an estimated 800 million people with mental health disorders worldwide, new treatment options could soon be available.

TOP TRENDING ARTICLES


PLEASE DISABLE AD BLOCKER TO VIEW DISQUS COMMENTS

Ad Blocking software disables some of the functionality of our website, including our comments section for some browsers.


Trending Now



BlackListed News 2006-2023
Privacy Policy
Terms of Service